Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Corbus Pharmaceuticals Holdings Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Corbus Pharmaceuticals Holdings şirketinin kazançlarının yıllık 29.2% oranında düşmesi, yıllık gelirinin ise yıllık 75.5% oranında artması bekleniyor. EPS'nin yıllık 9.4% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-29.2%

Kazanç büyüme oranı

-9.4%

EPS büyüme oranı

Biotechs kazanç büyümesi	34.8%
Gelir büyüme oranı	75.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	24 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:3371 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	5	-75	-60	-31	7
12/31/2025	1	-55	-44	-31	7
12/31/2024	N/A	-40	-46	-32	7
6/30/2024	N/A	-35	-30	-30	N/A
3/31/2024	N/A	-34	-29	-29	N/A
12/31/2023	N/A	-45	-36	-36	N/A
9/30/2023	N/A	-47	-38	-38	N/A
6/30/2023	N/A	-46	-38	-38	N/A
3/31/2023	N/A	-51	-42	-42	N/A
12/31/2022	N/A	-42	-38	-38	N/A
9/30/2022	N/A	-42	-40	-40	N/A
6/30/2022	0	-35	-32	-32	N/A
3/31/2022	0	-39	-37	-37	N/A
12/31/2021	1	-46	-48	-48	N/A
9/30/2021	2	-44	-57	-57	N/A
6/30/2021	3	-77	-85	-85	N/A
3/31/2021	3	-98	-94	-94	N/A
12/31/2020	4	-111	-100	-100	N/A
9/30/2020	6	-129	-106	-104	N/A
6/30/2020	7	-115	-97	-94	N/A
3/31/2020	36	-75	-87	-84	N/A
12/31/2019	36	-71	-48	-46	N/A
9/30/2019	35	-62	-39	-37	N/A
6/30/2019	34	-56	-30	-29	N/A
3/31/2019	6	-70	-19	-18	N/A
12/31/2018	5	-56	-32	-30	N/A
9/30/2018	3	-49	-28	-25	N/A
6/30/2018	3	-41	-25	-23	N/A
3/31/2018	2	-37	N/A	-23	N/A
12/31/2017	2	-32	N/A	-28	N/A
9/30/2017	3	-29	N/A	-24	N/A
6/30/2017	3	-28	N/A	-21	N/A
3/31/2017	3	-25	N/A	-18	N/A
12/31/2016	2	-20	N/A	-14	N/A
9/30/2016	2	-15	N/A	-9	N/A
6/30/2016	1	-12	N/A	-8	N/A
3/31/2016	1	-10	N/A	-6	N/A
12/31/2015	1	-9	N/A	-5	N/A
9/30/2015	0	-8	N/A	-5	N/A
6/30/2015	0	-6	N/A	-3	N/A
3/31/2015	N/A	-4	N/A	-4	N/A
12/31/2014	N/A	-3	N/A	-2	N/A
9/30/2014	N/A	-2	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	-1	N/A
3/31/2014	N/A	-1	N/A	0	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 3371 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 3371 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 3371 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 3371 şirketinin gelirinin (yıllık 75.5% ) German pazarından (yıllık 5.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 3371 şirketinin gelirinin (yıllık 75.5% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 3371 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Corbus Pharmaceuticals Holdings Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast to breakeven in 2024

Recent updates

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Negative shareholders equity

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering.

Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 (SYS6002)

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)

Corbus Pharmaceuticals Holdings, Inc. Presents Results of Two Pre-Clinical Studies on its Anti-VETA>8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. Appoints Anne Altmeyer to Board of Directors

First half 2022 earnings released: US$0.18 loss per share (vs US$0.28 loss in 1H 2021)

Corbus Pharmaceuticals Holdings Gets a 180-Day Extension to January 2, 2023, to Regain Compliance with the Minimum Bid Price Requirement

Corbus Pharmaceuticals Holdings, Inc. Enters into a Binding Term Sheet with Venn Therapeutics, LLC, to Resolve the Claims by Venn Against the Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Announces That New Preclinical Data for CRB-601 Are Being Presented in an Oral Presentation At the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference in New York

First quarter 2022 earnings released: US$0.075 loss per share (vs US$0.14 loss in 1Q 2021)

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 18, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Corbus Pharmaceuticals Holdings Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Third quarter 2021 earnings released: US$0.017 loss per share (vs US$0.43 loss in 3Q 2020)

Head of Research & Chief Medical Officer Barbara White has left the company

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.52 loss in 2Q 2020)

Corbus Pharmaceuticals Holdings, Inc.(NasdaqGM:CRBP) dropped from Russell 3000E Growth Index

Corbus Pharmaceuticals Announces Topline Results from Determine Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Corbus Pharmaceuticals Holdings, Inc. Announces Licensing Deals for Two New Monoclonal Antibodies, CRB-601 and CRB-602 to Further Expand Pipeline into Cancer and Fibrotic Diseases

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.43 loss in 1Q 2020)

Full year 2020 earnings released: US$1.42 loss per share (vs US$1.12 loss in FY 2019)

Corbus Pharmaceuticals Holdings, Inc. Provides Clinical Program Updates

Corbus Pharmaceuticals Holdings, Inc. to Report Q4, 2020 Results on Mar 15, 2021

New 90-day high: €1.87

New 90-day high: €1.25

Corbus Pharmaceuticals Holdings, Inc. Announces the Resignation of Robert Discordia as Chief Operating Officer

Corbus Pharmaceuticals Holdings, Inc. Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Robert Discordia Will No Longer Serve as Chief Operating Officer of Corbus Pharmaceuticals Holdings, Inc

New 90-day low: €1.01

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

New 90-day high - €7.81

Corbus Pharmaceuticals Holdings, Inc. to Report Q2, 2020 Results on Aug 06, 2020

New 90-day low - €5.38

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin